An experimental diabetes drug, TAK-875, demonstrated its ability to improve blood-sugar control with a low risk of hypoglycemia, according to phase 2 study results published online February 27 in The Lancet.
Read more
TAK-875 controls blood sugar, reduces hypoglycemia risk
Posted in Drugs